Follow the latest Eli Lilly & Co. (LLY) news and market headlines alongside the live LLY price. Stay informed on what's moving LLY.
Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 30.78% on an annualized basis producing an average annual return of 40.82%. Currently, Eli Lilly has a market capitalization of $1.27 trillion.
As tech stocks struggle post-election, investors are rotating into defensive sectors like healthcare. The State Street Healthcare Select Sector SPDR ETF (XLV) has gained 23% in 2026, outperforming the S&P 500's 11% return. Healthcare's inelastic demand makes it attractive during market volatility, though investors should consider dollar-cost averaging given the recent run-up.
Viking Therapeutics is conducting phase 3 trials for its obesity drug VK2735 in both injectable and oral forms. The oral formulation could expand the addressable market through a dual-dosing strategy. With conservative assumptions of 50% phase 3 success rate and 10% market share of tirzepatide's peak sales, Viking's stock could reach $110 per share by 2028, making a $10,000 investment worth up to $47,800.
Facility will manufacture injectable medicines, including retatrutideSite will create 850 high-wage jobs and 2,000 construction jobsINDIANAPOLIS, Nov. 12, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today
AbbVie reported strong Q3 2026 results with immunology revenues rising 16.6% to $9.2 billion, driven by blockbuster drugs Skyrizi (up 22.9%) and Rinvoq (up 24.3%), offsetting Humira's 30.6% decline due to biosimilar competition. The company raised 2026 sales forecasts for both drugs, expecting combined growth exceeding 20%, with new indications in inflammatory bowel disease and dermatology providing additional growth opportunities.
Eli Lilly wins China approval for its first GLP-1 weight-loss pill, gaining an early edge in the country's $4.5 billion market.
Eli Lilly has established itself as a dominant player in the obesity treatment market, with Mounjaro and Zepbound generating 65% of revenues. The company's April 2026 launch of Foundayo (oral GLP-1) recorded $281 million in sales, offering a more convenient alternative to injectable treatments. Lilly is developing next-generation therapies including retatrutide (triple-acting), eloralintide, and EloraTZP to maintain market leadership. However, competition is intensifying from Novo Nordisk and emerging biotech companies.
Novo Nordisk exceeded JPMorgan's expectations with strong Wegovy pill sales, accumulating over 8 million prescriptions. However, the company is in a transition phase toward a high-volume/low-price model, causing operating profit to fall 9% year-over-year. While the stock has fallen 70% from its 2024 peak and offers an attractive 4.4% dividend yield, investors should weigh the company's strategic shift against competition from Eli Lilly and other GLP-1 drug makers.
Eli Lilly raised its 2026 sales forecast to $91-92 billion, driven by strong Zepbound weight-loss drug sales. While smaller competitor Viking Therapeutics shows promise with its VK2735 candidate demonstrating encouraging clinical trial results, Eli Lilly's diversified pipeline and market leadership position it well to withstand competition. Viking offers high upside potential but carries significant clinical and regulatory risks.
The article compares two pharmaceutical giants for 2027 investment. Johnson & Johnson offers stability with a 6% revenue growth, lower P/E ratio of 42.59, and strong free cash flow of $19.7B, but faces patent expirations and litigation risks. Eli Lilly demonstrates explosive 44.7% revenue growth driven by GLP-1 drugs like Mounjaro and Zepbound, commanding a premium valuation (P/E 47.05), with significant future growth potential but concentrated revenue dependency.
DelveInsight released a comprehensive competitive landscape report on GLP-1 receptor agonists and incretin-based therapies, covering 200+ pipeline drugs from 180+ active players. The report highlights approved drugs like MOUNJARO (tirzepatide) and OZEMPIC (semaglutide), with 30+ therapies in late-stage development and 60+ in mid/early stages. Key indications include obesity, type 2 diabetes, and cardiovascular outcomes. Recent developments include positive Phase III results for retatrutide, survodutide, and other dual/triple agonists from major pharmaceutical companies.
Eli Lilly's Foundayo showed promising Phase 3 results reducing sleep apnea severity by 43.8%, but the FDA ordered warnings about rare vision-loss condition (NAION) on GLP-1 drug labels. Despite regulatory headwinds, the obesity drug market remains robust with 1.1 billion obese people globally. Healthcare ETFs offer diversified exposure to GLP-1 manufacturers while mitigating company-specific risks, with Eli Lilly holding top positions across major healthcare funds.
Novo's newly launched Wegovy oral pill generated DKK 5.4 billion in Q3 2026 sales with 3.6 million U.S. prescriptions, prompting the company to raise its 2026 growth outlook. However, the company faces intense competition from Eli Lilly's surging Mounjaro and Zepbound sales, as well as emerging competitors like Viking Therapeutics and Structure Therapeutics developing alternative GLP-1 therapies. Novo's stock has underperformed the industry year-to-date, trading at a discount valuation.
The iShares U.S. Pharmaceuticals ETF (IHE) has surged 42.76% from its 52-week low and recently hit a 52-week high, driven by strong drug demand, promising clinical developments, and M&A activity in the pharmaceutical sector. The fund's largest holding, Eli Lilly, received a price target increase from Jefferies to $1,700, citing underappreciated growth potential in international GLP-1 markets. With a positive weighted alpha of 38.85, the ETF may continue its strong performance in the near term, though it carries a high-risk outlook.
AbbVie raised its 2026 revenue guidance to $67.8 billion for the third time this year, driven by strong performance from Skyrizi and Rinvoq, which are offsetting Humira's patent-driven decline. The company's neuroscience portfolio, including Vyalev and migraine drugs, is also contributing to growth. However, aesthetics sales remain soft and oncology growth is subdued. AbbVie maintains a Zacks Rank #3 (Hold) rating with solid long-term prospects.
The article discusses a long-term investment strategy for building a 'forever portfolio' with stocks suitable for buy-and-hold investors. It emphasizes the importance of adopting a different mindset when investing for longer time horizons, though the specific stock recommendations are behind a paywall.
Browse other US stocks in the same sector as Eli Lilly & Co.
See US stocks with the highest market capitalization
Discover today's most actively traded US stocks
Browse today's leading gainers in the US stock market
Explore the cryptocurrencies with the highest market capitalization
News and data on this page is provided by our partnered third-party news and market data provider, with the original publisher credited on each article. All third-party content reflects the views of the original publisher and does not represent the views of MEXC. Price and market data shown on this page are provided by third-party data providers and may be delayed. MEXC offers trading products related to LLY, including RealStocks and Stock Futures.
The content on this page is provided for informational purposes only and does not constitute investment, financial, or trading advice. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of any news or market data shown. Trading U.S. stocks and related products involves significant risk, and prices can move sharply in a short period. Past performance does not guarantee future results. Please conduct your own research and assess your financial situation and risk tolerance before making any investment decisions. MEXC is not liable for any losses arising from the use of this information.